Status:
TERMINATED
Application of Daptomycin in MRSA Infected Diabetic Foot in Comparison to Vancomycin Treatment
Lead Sponsor:
Ruhr University of Bochum
Conditions:
Diabetic Foot
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
Objective of the study is to test whether Daptomycin (6 mg/kg bodyweight) is non-inferior in treatment of severe diabetic foot infections (MRSA) in comparison to antibiotic treatment with Vancomycin (...
Eligibility Criteria
Inclusion
- Type 1 and Type 2 Diabetes mellitus
- MRSA infected foot ulcus Wagner 1-2 without primary surgical intervention
- Therapy duration will last at least more than 5 days
- men and women age 18 - 80 years
- Declaration of patient's consent
- Ability and willingness to give written informed consent and to comply with the requirements of the study
- Sexually active females, unless surgically sterile, must be willing to use 2 forms of contraception through the end of the study. Sexually active woman must, except if they were surgically sterilized, have to use for already 30 days before first dose of study medication an effective method of pregnancy prevention. Acceptable forms of contraception for female subjects include: oral, transdermal, injectable or implanted contraceptives, intrauterine device (IUD), female condom, diaphragm with spermicide, cervical cap, absolute waiver of sexual intercourse, use of a condom by the sexual partner, or sterile sexual partner. Male subjects with partners of child-bearing potential should use barrier contraception in addition to having their partners use another method of contraception.
Exclusion
- Osteomyelitis according to international consensus guideline (3 of 5 criteria apply for diagnosis)
- Presence of a severe nephropathy (creatinine clearance \< 30 ml/min)
- Advanced diabetic retinopathy
- Simultaneous participation in another study or participation in a study in the past 30 days
- Non permissible concomitant medication e.g. therapy regimen using several antibiotics
- Contraindication for antibiotics
- Dialysis essential
- Pregnancy (to be determined by pregnancy test) or unsafe contraception
- Neutropenia
- immunosuppression (oral immunosuppressives, Corticoids exaggerating 7.5 mg Prednisolon-equivalents)
- Chronic liver disease (AST or ALT increased to 10fold, bilirubin increased to threefold compared to normal values)
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT01199783
Start Date
July 1 2011
End Date
December 1 2013
Last Update
March 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Herz- und Diabeteszentrum
Bad Oeynhausen, Germany, 32545